News related to
China

The United States has imposed a 26% tariff on Indian imports, intensifying trade tensions between the two nations. This measure, announced by President Donald Trump on April 2, 2025, is part of a broader strategy targeting countries with which the U.S. has significant trade deficits. The baseline 10% tariff will take effect on April 5, with the additional 16% following on April 9.

President Trump has consistently criticized India’s trade policies, labeling the nation as a “tariff king” and a “big abuser” of tariffs. The administration justifies the new tariffs by pointing to the disparity between the U.S.’s 2.5% tariff on passenger vehicle imports and India’s 70% tariff on similar American products.

Indian officials have expressed mixed reactions to the announcement. A senior government representative described the development as a “mixed bag,” emphasizing that it is not perceived as a significant setback. The commerce ministry is currently evaluating the potential impact of these tariffs on the Indian economy.

The sectors most vulnerable to the increased tariffs include pharmaceuticals, textiles, and automotive parts, which constitute a substantial portion of India’s exports to the U.S. Analysts predict that these industries may experience a decline in competitiveness within the American market, potentially leading to decreased export volumes and revenue losses.

In an effort to mitigate the impact of the tariffs and foster better trade relations, India has proposed reducing tariffs on certain U.S. agricultural products, such as almonds, cranberries, and bourbon whiskey. This initiative aims to facilitate a more favorable trade agreement between the two countries.

Despite these conciliatory efforts, the U.S. proceeded with the tariff imposition. The move has elicited concerns among Indian policymakers and industry leaders about the potential escalation of a trade war and its ramifications on the domestic economy. The Confederation of Indian Industry has urged the government to engage in diplomatic negotiations to resolve the dispute amicably.

The global community is closely monitoring the situation, as the U.S.’s tariff measures have affected multiple countries, including China, the European Union, and Japan. The European Commission has criticized the tariffs as a severe blow to the global economy, while other nations have signaled intentions to retaliate or seek negotiations.

Pfizer has unveiled its new research and development centre in Beijing, marking a significant step in the company’s strategic expansion in China. The facility, located within the BioPark in the Beijing Economic-Technological Development Area , represents the pharmaceutical giant’s ongoing commitment to increasing its presence in the Chinese market. This development comes at a time when global healthcare companies are intensifying their focus on innovation in key Asian markets.

The opening of the R&D centre is expected to bolster Pfizer’s research capabilities, particularly in the development of cutting-edge treatments in areas such as oncology, vaccines, and rare diseases. The new centre will serve as a hub for collaborative efforts between Pfizer and local Chinese researchers, healthcare providers, and academic institutions. This collaboration is viewed as a strategic move to accelerate the discovery and delivery of new therapies tailored to both global and regional healthcare needs.

Pfizer’s decision to open a new R&D centre in Beijing underscores the company’s long-term investment in China’s growing pharmaceutical industry. It is also a response to the Chinese government’s push to modernise its healthcare infrastructure and increase the availability of advanced medical treatments to its population. China’s robust investment in healthcare innovation and its vast population present a significant opportunity for Pfizer to lead in areas of unmet medical need.

The Beijing facility will focus on the integration of new technologies, such as artificial intelligence and data analytics, into drug discovery and clinical development processes. These technologies are expected to streamline Pfizer’s ability to identify promising drug candidates more efficiently, reducing development timelines and improving outcomes for patients worldwide. The centre will also support the company’s efforts to create vaccines and treatments specifically designed for the Chinese market.

Local Chinese health experts have welcomed the initiative, highlighting the positive impact it is likely to have on the region’s pharmaceutical ecosystem. Collaborations between international pharmaceutical companies like Pfizer and domestic research institutions are seen as vital to addressing health challenges in China, including the increasing prevalence of chronic diseases and an ageing population. The government’s support of such ventures is also expected to foster a more innovative and competitive environment in the Chinese pharmaceutical sector.

Pfizer’s expansion into Beijing is not the company’s first move in the region. Over the past decade, the pharmaceutical leader has steadily increased its investments in China, with a particular focus on expanding its clinical trials and vaccine development operations. This new R&D centre further cements the company’s position as a key player in the Chinese healthcare landscape.

One of the critical drivers behind Pfizer’s decision to build the facility in Beijing is the strategic importance of the region’s role in global drug development. The Chinese market, one of the largest in the world, has seen rapid growth in demand for healthcare products, particularly in biotechnology, oncology treatments, and vaccines. With an increasingly affluent population, China’s demand for high-quality medical products has surged, presenting a strong business case for Pfizer to deepen its engagement with the market.

The opening of this facility aligns with Pfizer’s broader global strategy to strengthen its innovation pipeline and maintain its competitive edge in the pharmaceutical industry. The company has consistently emphasised the importance of R&D as a cornerstone of its business model, and this move further emphasises its commitment to discovering new therapies for complex diseases. The Beijing centre is expected to collaborate with Pfizer’s other global R&D hubs, contributing to a more interconnected and agile research network.

Pfizer’s global operations have also faced some challenges in recent years, particularly with the economic uncertainties brought on by the pandemic. However, the company’s strategy of investing in emerging markets like China reflects its resilience and focus on future growth. By establishing a physical presence in one of the world’s most dynamic pharmaceutical markets, Pfizer is positioning itself to tap into both immediate and long-term opportunities in China and beyond.

The Chinese government has been supportive of multinational companies that invest in high-tech industries such as pharmaceuticals and biotechnology. This policy environment has made it increasingly attractive for foreign companies to set up R&D centres and collaborate with Chinese firms. In return, China benefits from the influx of advanced medical technologies and expertise, further propelling its ambitions to become a leader in global healthcare innovation.

Pfizer’s Beijing R&D centre is part of a broader trend of Western pharmaceutical companies making significant investments in China. These companies are increasingly collaborating with local research institutions to foster innovation, improve patient care, and support the country’s healthcare development goals. Such investments are also aligned with China’s ongoing reforms aimed at modernising its healthcare system, ensuring broader access to innovative treatments, and addressing the nation’s rising health challenges.

The opening of the R&D centre also highlights Pfizer’s commitment to ensuring that new therapies developed in Beijing will be available not only to the Chinese market but also to the global community. With the centre poised to focus on therapies for diseases with high unmet needs, including cancer and infectious diseases, the potential for cross-border medical collaboration is immense. Pfizer’s ability to leverage the centre’s local expertise and technological advancements will play a crucial role in meeting both Chinese and global healthcare demands.

President Donald Trump has indicated that his first international trip in his second term will likely include visits to key countries in the Middle East, namely Saudi Arabia, the United Arab Emirates , and Qatar. While speaking to the press in the Oval Office, Trump suggested the visit could occur next month, though he noted it might be slightly delayed depending on diplomatic and scheduling considerations.

This trip is expected to be a crucial moment in Trump’s foreign policy, as it will focus on reinforcing the United States’ strategic relationships in the region, particularly in the wake of his administration’s efforts to reshape the dynamics of the Middle East through initiatives such as the Abraham Accords and military partnerships. The planned visit underscores the ongoing importance of these Gulf nations as key players in both regional and global geopolitical matters, including security, energy, and economic cooperation.

The president’s statement reflects the evolving nature of U.S. foreign policy in the Middle East, where traditional alliances have been reinforced while new partnerships, especially with the UAE and Bahrain, have emerged over the past few years. The Abraham Accords, signed in 2020, have opened new avenues for diplomatic engagement in the region, with several Arab countries normalising ties with Israel, a move that has significantly altered the political landscape.

Saudi Arabia, as a longstanding ally of the United States, remains at the heart of the Middle East’s geopolitics, particularly in relation to energy markets and security concerns regarding Iran’s growing influence. Trump’s administration was marked by its staunch support for the kingdom, including a controversial stance on the murder of journalist Jamal Khashoggi and its military cooperation in the region. A visit to Riyadh would likely reaffirm these strategic ties, especially as the U.S. continues to grapple with Iran’s nuclear ambitions and its role in regional instability.

The UAE has also become an increasingly influential partner, not only in terms of energy and security but also in fostering technological innovation and investment. In addition to hosting Israeli diplomatic missions following the Abraham Accords, the UAE has positioned itself as a hub for economic development, hosting major events like Expo 2020 Dubai and advancing its space exploration programme. Trump’s engagement with the UAE signals an ongoing commitment to strengthen ties with nations that have emerged as leaders in the Middle East’s economic diversification efforts.

Qatar, a key player in regional diplomacy and a host to the massive U.S. military base at Al Udeid, will also play a central role in Trump’s plans. As a small but influential country, Qatar has positioned itself as a mediator in various regional conflicts, often serving as an intermediary between conflicting parties in the region. Trump’s relationship with Qatar has been critical, particularly in relation to military cooperation and counter-terrorism efforts, and his visit would likely reaffirm the importance of these ongoing collaborations.

While the specifics of the trip remain unclear, the White House has made it known that the president’s travels will reflect the continued prioritisation of U.S. interests in the Middle East. Following years of tension over issues such as the U.S. withdrawal from Afghanistan and its approach to Iran, the Middle East remains a focal point of U.S. foreign policy. This visit could signal a shift towards a more engaged and active approach, particularly as the region faces new challenges ranging from economic instability to security threats from non-state actors.

Experts suggest that Trump’s trip will also serve as a signal to other global powers, particularly China and Russia, of the U.S.’s commitment to maintaining its influence in the Middle East. The region’s role in global energy production, combined with its strategic location at the crossroads of Europe, Africa, and Asia, makes it a critical area for U.S. interests. Trump’s visit is expected to focus on advancing energy partnerships, countering the growing influence of China in the region, and ensuring that U.S. military presence continues to be a stabilising factor in the face of Iranian provocations and broader geopolitical shifts.

Trump’s visit comes at a time when the Middle East is witnessing significant shifts in its diplomatic and economic alignments. Saudi Arabia, for example, has begun to recalibrate its foreign policy, striking deals with China and Russia, and there are signs that the kingdom is exploring new relationships outside its traditional Western alliances. Trump’s visit could also serve to counter these new trends, reinforcing U.S. leadership in the region.

The trip could be particularly significant for the future of U.S. relations with Israel. Although Israel’s peace agreements with several Arab states have altered the region’s political landscape, U.S. support for Israel remains a cornerstone of its Middle East policy. Trump’s visit will likely address how the U.S. plans to build on these agreements while navigating the evolving dynamics between Israel and its Arab neighbours.

As Trump prepares for his visit, discussions will also revolve around the broader implications of his foreign policy agenda. The Middle East is not only a region of military importance but also a key player in the global fight against terrorism, as well as in shaping energy markets and technological innovations. Trump’s emphasis on strengthening partnerships with countries like Saudi Arabia, the UAE, and Qatar will be crucial in setting the tone for the next phase of U.S. involvement in the region.

Foxconn, Apple’s primary manufacturing partner, plans to produce 25 to 30 million iPhones in India this year, more than doubling its output from the previous year. This move underscores Apple’s strategy to strengthen its manufacturing footprint in India and diversify its supply chain amid global uncertainties.

The Taiwanese contract manufacturer has been conducting trial runs at its facility in Bengaluru, Karnataka, aiming to meet Apple’s stringent quality standards and production targets. This initiative aligns with Apple’s broader objective to reduce reliance on Chinese manufacturing and mitigate risks associated with geopolitical tensions and supply chain disruptions.

Foxconn’s expansion in India is part of a larger trend of global tech companies seeking alternative manufacturing hubs. India’s Production-Linked Incentive scheme has been instrumental in attracting such investments by offering financial incentives to boost domestic manufacturing. In the fiscal year ending March 2023, Foxconn produced approximately ₹300 billion worth of iPhones, surpassing the PLI scheme’s cap of ₹200 billion, indicating the program’s success in scaling up production.

In addition to iPhone assembly, Apple is broadening its product manufacturing in India. A unit of Foxconn is set to commence the assembly of AirPods at a new factory near Hyderabad, Telangana, by early 2025, following successful trial productions. This diversification reflects Apple’s commitment to expanding its product assembly capabilities within the country.

However, the expansion has encountered challenges. Reports suggest that China is imposing restrictions on the movement of employees and specialized equipment essential for high-tech manufacturing to India and Southeast Asia. These measures appear aimed at limiting technology transfers and mitigating potential job losses, posing obstacles to Apple’s efforts to diversify its production bases.

Despite these hurdles, Apple’s manufacturing partners in India are making significant strides. Tata Electronics has acquired a 60% stake in Pegatron Technology India, which manages an iPhone plant near Chennai. This acquisition positions Tata as a formidable competitor to established players like Foxconn in the Indian iPhone manufacturing landscape.

The Indian government’s support has been pivotal in this expansion. Foxconn is establishing a mobile phone manufacturing plant in the Devanahalli Industrial Area, Bengaluru, with an investment of ₹21,911 crore. The company will receive incentives amounting to ₹6,970 crore under the Electronics System Design and Manufacturing policy, as announced by Karnataka’s Chief Minister.

China’s cloud computing sector is on track for substantial expansion in 2025, driven by increased investments from major technology firms and a surge in demand for artificial intelligence capabilities. Industry projections indicate that the public cloud market in China is expected to reach $74.13 billion in 2025, with Infrastructure as a Service leading the segment.

In the third quarter of 2024, spending on cloud infrastructure services in mainland China grew by 11% year-over-year, totaling $10.2 billion. This growth marks a return to double-digit increases, highlighting the sector’s resilience and upward trajectory.

Leading Chinese tech companies are making significant investments to bolster their cloud and AI infrastructure. Alibaba Cloud, for instance, announced a $52.6 billion investment over three years to enhance its cloud computing and AI capabilities. Similarly, Meituan has committed billions toward acquiring chips for AI model training, underscoring the competitive drive among Chinese firms to advance in the AI arena.

Despite these aggressive investments, concerns about potential overcapacity in AI data centers have emerged. Alibaba Chairman Joe Tsai cautioned about a possible bubble in AI data center construction, noting that substantial investments are being made without guaranteed future demand. He highlighted that major tech companies are investing heavily in AI infrastructure, which may not be justified by future needs.

In the global context, Chinese cloud providers are expanding their presence overseas. Alibaba Cloud, for example, launched its first data center in Mexico, marking its entry into the Latin American market and reflecting a broader strategy to extend its global footprint.

While China’s cloud market is experiencing robust growth, it still trails behind global leaders. In the fourth quarter of 2024, worldwide cloud infrastructure services spending reached $86 billion, with Amazon Web Services maintaining a 33% market share. In comparison, Alibaba Cloud held approximately 4% of the global market during the same period.

The imposition of a 25% tariff on auto imports by U.S. President Donald Trump has intensified fears of a global trade war, prompting investors to seek refuge in safe-haven assets like gold. The tariffs have particularly impacted the auto industries in Japan and South Korea, leading to notable declines in their stock markets. Japan’s Nikkei index dropped over 2%, while South Korea’s benchmark index fell to a two-week low. In contrast, Hong Kong’s Hang Seng index remained relatively stable, rising by 0.6%. The auto sector, vital to both South Korea and Japan, faces significant challenges, with some manufacturers considering production relocations or price adjustments.

The escalating trade tensions have heightened investor anxiety, leading to increased demand for gold as a safe-haven asset. Analysts attribute the surge in gold prices to factors such as U.S. trade and fiscal policies, slowing economic growth, and geopolitical conflicts. Financial analyst Kyle Rodda emphasized that these elements collectively bolster gold’s appeal. Additionally, gold tends to benefit in low-interest-rate environments and during periods of political and economic uncertainty.

In response to the rising gold prices, Goldman Sachs has revised its year-end forecast for the metal from $3,100 to $3,300 per ounce. Analysts Lina Thomas and Daan Struyven cited higher-than-expected inflows into gold exchange-traded funds and robust central bank demand, particularly from large Asian central banks, as key drivers for the upward revision. They anticipate that these central banks will continue aggressive gold purchases over the next three to six years. The analysts also suggested potential entry points for investors, including a resolution to the Russia-Ukraine conflict or a significant equity market downturn.

The surge in gold prices has led to a notable increase in the sale of old jewelry and coins in major markets across Asia and the Middle East. Consumers in countries like India, China, and the United Arab Emirates are capitalizing on the high prices to liquidate their gold holdings, potentially reducing imports and tempering the gold rally. In India, domestic gold prices have risen more than 32%, prompting many to sell rather than purchase new jewelry. Similar trends are observed in Dubai and China, where high prices have led consumers to sell or hold onto their gold assets.